48例阿莫西林致药疹住院病例分析

doi:10.19803/j.1672-8629.2020.09.09

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (9): 583-588.
DOI: 10.19803/j.1672-8629.2020.09.09

48例阿莫西林致药疹住院病例分析

朱冬春¹, 孙旭群^1,*, 蒋海峰², 王玉山¹, 方先骏¹, 夏泉¹

¹安徽医科大学第一附属医院药剂科,国家中医药管理局中药化学三级实验室,安徽合肥 230022;
²安徽医科大学临床药理研究所,安徽合肥 230032

收稿日期:2020-08-17 修回日期:2020-08-17 出版日期:2020-09-15 发布日期:2020-08-17
通讯作者: ^*孙旭群,女,硕士,副主任药师·硕导,药品不良反应监测与临床药学。E-mail:sunxq5000@sina.com
作者简介:朱冬春,男,硕士,主管药师,临床药学。

Analysis of 48 Cases of Drug Eruptions Induced by Amoxicillin

ZHU Dongchun¹, SUN Xuqun^1,*, JIANG Haifeng², WANG Yushan¹, FANG Xianjun¹, XIA Quan¹

¹Department of Pharmacy, the First Affiliated Hospital of Anhui Medical University, Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of Traditional Chinese Medicine, Hefei Anhui 230022, China;
²Institute of Clinical Pharmacology, Anhui Medical University, Hefei Anhui 230032, China

Received:2020-08-17 Revised:2020-08-17 Online:2020-09-15 Published:2020-08-17

摘要/Abstract

摘要： 目的了解阿莫西林所致药疹的临床特征,为药品不良反应防治提供参考。方法分析某三甲医院2016年至2018年期间,因阿莫西林相关药疹收治住院患者的临床资料。结果 48例阿莫西林相关的药疹住院病例,涉及阿莫西林41例,阿莫西林克拉维酸钾7例。呼吸道感染、消化道幽门螺旋杆菌感染是主要的用药原因。患者平均年龄(42.94±20.78)岁,其中29.17%患者既往有阿莫西林或青霉素过敏史。药疹潜伏期在7 d内占86.67%,其中1 d以内占35.56%;平均住院日(8.42±4.83)d。住院期间使用糖皮质激素[以氢化可的松计,M(P₂₅,P₇₅)]1 580.00(625.00,2 470.00) mg,使用阿莫西林与阿莫西林克拉维酸钾导致药疹的病例在住院日、糖皮质激素用量的差异无统计学意义(P =0.797,P =0.977);药疹患者有68.75%合并白细胞异常,有29.17%合并肝脏生化学检查异常。结论阿莫西林相关药疹潜伏期较短,及时诊治预后较好,需警惕血液系统异常以及肝损伤,使用阿莫西林需加强对患者过敏史的关注。

关键词: 阿莫西林, 药疹, 不良反应

Abstract: Objective To investigate the characteristics of amoxicillin-related drug eruptions and provide reference for the corresponding prevention and treatment of adverse drug reactions. Methods Analysis of inpatients admitted to a tertiary hospital between 2016 and 2018 for drug eruptions was conducted. Cases of amoxicillin-related drug eruptions were screened out, and patients' conditions and treatment outcomes were analyzed. The related data was obtained from the Hospital Information System (HIS). Results It was found that there were 48 cases of amoxicillin-related drug eruptions among the hospitalized patients, 41 of which involved amoxicillin and 7 involved amoxicillin/ clavulanate potassium. The mean age of the patients was 42.94 ± 20.78 years old. Among them, 14 patients had a previous history of allergy to amoxicillin or penicillin (29.2%). Respiratory tract infections and Helicobacter pylori infections were the main reason for medication. The incubation period of drug eruptions was within 1 day in 35.56% of the patients, and within 7 days in 86.67% of the patients after administration. The average length of hospital stay was 8.42±4.83 days, and cumulative dose of glucocorticoids (in terms of hydrocortisone) used during the hospital stay was 1 580.00(625.00, 2 470.00) mg. There was no statistically significant difference in the length of hospital stay(P =0.797)or the cumulative dose of glucocorticoids(P =0.977) between cases of drug eruptions related to amoxicillin and amoxicillin/ clavulanate potassium respectively. More patients were found to have abnormal levels of white blood cells (68.75%) and liver biochemical examination (29.17%). Conclusion The incubation period of amoxicillin-related drug eruptions is generally short, and it is within one week in most patients. There are no significant differences in severity and treatment outcomes of drug eruptions between amoxicillin and amoxicillin/clavulanate potassium. In case of drug eruptions, we need to be alert to blood system abnormalities and liver damage. Drug eruptions can have good prognosis after quick diagnosis and treatment. Attention must be paid to the patient's allergy history when such antibiotics as amoxicillin are prescribed.

Key words: amoxicillin, drug eruption, adverse reactions

中图分类号:

R994.11

朱冬春, 孙旭群, 蒋海峰, 王玉山, 方先骏, 夏泉. 48例阿莫西林致药疹住院病例分析[J]. 中国药物警戒, 2020, 17(9): 583-588.

ZHU Dongchun, SUN Xuqun, JIANG Haifeng, WANG Yushan, FANG Xianjun, XIA Quan. Analysis of 48 Cases of Drug Eruptions Induced by Amoxicillin[J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 583-588.

参考文献

[1] 贾宏军, 郑晓辉, 赵振营. 新版《抗菌药物临床应用指导原则》(2015)的解读[J]. 天津药学, 2016, 28(5): 46-48.
[2] 刘亚美, 曹育春. 抗菌药物致药疹65例临床分析[J]. 医药导报, 2019, 38(12): 1601-1604.
[3] Zalewska-Janowska A, Spiewak R, Kowalski ML.Cutaneous Manifestation of Drug Allergy and Hypersensitivity[J]. Immunol Allergy Clin North Am, 2017, 37(1): 165-181.
[4] 赵娜, 刘伟, 白霞凤. 注射用美罗培南致红皮病型药疹1例[J]. 中国药物警戒, 2019, 16(11): 697-698.
[5] 曹媛, 邓蓉蓉, 夏延哲. 36例重型药疹分析[J]. 中国药事, 2016, 30(5): 522-526.
[6] 胡廷婷, 徐珽. 硫酸氢氯吡格雷片致大疱表皮松解型药疹1例[J]. 中国药物警戒, 2019, 16(7): 442-443,446.
[7] Zhang C, Van DN, Hieu C, et al.Drug-induced severe cutaneous adverse reactions: Determine the cause and prevention[J]. Ann Allergy Asthma Immunol, 2019, 123(5): 483-487.
[8] Shenoy ES, Macy E, Rowe T, et al.Evaluation and Management of Penicillin Allergy: A Review[J]. JAMA, 2019, 321(2): 188-199.
[9] Kornmehl H, Gorouhi F, Konia T, et al.Generalized fixed drug eruption to piperacillin/tazobactam and review of literature[J]. Dermatol Online J, 2018, 24(4): 14-18.
[10] 杨凡萍, 陈圣安, 朱沁媛, 等. 1883例住院药疹患者致敏药物分析[J]. 中华临床免疫和变态反应杂志, 2017, 11(3): 232-240.
[11] Jha N, Alexander E, Kanish B, et al.A Study of Cutaneous Adverse Drug Reactions in a Tertiary Care Center in Punjab[J]. Indian Dermatol Online J, 2018, 9(5): 299-303.
[12] 吴小枫, 林珍, 李扬, 等. 346例药疹病例回顾性分析[J]. 中国药物警戒, 2019, 16(3): 149-153.
[13] 卫生部. 糖皮质激素类药物临床应用指导原则(节选)[J]. 药物不良反应杂志, 2011, 13(1): 40-44.
[14] 付晓丹, 傅祥评, 杨凡萍, 等. 住院药疹922例临床分析[J]. 中华皮肤科杂志, 2015, 48(12): 867-870.
[15] 谢建翔, 张丽. 重症药疹297例分析[J]. 中国医院药学杂志, 2014, 34(3): 247-249.
[16] 伍伟, 唐彪, 宋家俊, 等. 344例药疹住院患者临床分析[J]. 皖南医学院学报, 2019, 38(6): 546-548.
[17] 李捷, 毛曼云, 唐妮, 等. 126例重症药疹住院患者的临床特征及预后[J]. 中南大学学报(医学版), 2017, 42(8): 953-957.
[18] Thakkar S, Patel TK, Vahora R, et al.Cutaneous Adverse Drug Reactions in a Tertiary Care Teaching Hospital in India: An Intensive Monitoring Study[J]. Indian J Dermatol, 2017, 62(6): 618-625.
[19] Demoly P, Adkinson NF, Brockow K, et al.International Consensus on drug allergy[J]. Allergy, 2014, 69(4): 420-437.
[20] Demoly P, Castells M.Important questions in drug allergy and hypersensitivity: consensus papers from the 2018 AAAAI/WAO international drug allergy symposium[J]. World Allergy Organ J, 2018, 11(1): 42-46.
[21] Bircher AJ, Scherer K.Delayed cutaneous manifestations of drug hypersensitivity[J]. Med Clin North Am, 2010, 94(4): 711-725.
[22] Deng Y, Li S, Zhang L, et al.Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: A meta-analysis[J]. Seizure, 2018, 60(8): 163-171.
[23] 陈梦, 李伟, 王雪, 等. 药物类过敏反应发生机制及临床前评价方法研究进展[J]. 中国新药杂志, 2017, 26(1): 51-59.
[24] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 中华肝脏病杂志, 2015, 23(11): 810-820.
[25] 庞宁, 郭代红, 寇炜, 等. 奥美拉唑相关肝功能异常与肝损害的自动监测对比研究[J]. 中国药物警戒, 2019, 16(4): 219-222.
[26] European Association for the Study of the Liver. Electronic Address E E E, Clinical Practice Guideline Panel C, Panel M, et al. EASL Clinical Practice Guidelines: Drug-induced liver injury[J]. J Hepatol, 2019, 70(6): 1222-1261.
[27] 贾东岗, 赵婉珍, 雷招宝. 阿莫西林-克拉维酸钾的肝毒性反应[J]. 药物不良反应杂志, 2010, 12(1): 37-41.
[28] Salvo F, Polimeni G, Moretti U, et al.Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy[J]. J Antimicrob Chemother, 2007, 60(1): 121-126.
[29] 崔黎. 阿莫西林与阿莫西林-克拉维酸钾临床不良反应对比分析[J]. 临床医药文献电子杂志, 2019, 6(71): 166,176.
[30] 胡俊华, 孟秋媛, 胡艳秋. 阿莫西林与阿莫西林-克拉维酸钾不良反应的对比研究[J]. 中国初级卫生保健, 2018, 32(4): 74-75.
[31] 刘皈阳, 于锋英, 陈超, 等. 阿莫西林与阿莫西林-克拉维酸钾不良反应的对比研究[J]. 药物不良反应杂志, 2010, 12(6): 397-400.
[32] Torres MJ, Montanez MI, Ariza A, et al.The role of IgE recognition in allergic reactions to amoxicillin and clavulanic acid[J]. Clin Exp Allergy, 2016, 46(2): 264-274.
[33] 朱扣柱, 陈艳华, 洪远. 注射用哌拉西林钠他唑巴坦钠致小儿重症药疹1例[J]. 中国药物警戒, 2019, 16(9): 568-569.

48例阿莫西林致药疹住院病例分析

Analysis of 48 Cases of Drug Eruptions Induced by Amoxicillin

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	朱盈, 沈璐, 李岚, 吴建民, 高晓洁. 新法规体系下我国牙膏不良反应监测工作分析与思考[J]. 中国药物警戒, 2024, 21(2): 219-222.
[9]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[10]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[11]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[12]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[13]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[14]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[15]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.